Histogenics Corp. Company Profile (NASDAQ:HSGX)

About Histogenics Corp.

Histogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company's product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee. NeoCart is a cartilage-like implant created using a patient's own cartilage cells through a series of tissue engineering processes. The patient's cells are separated from a tissue biopsy specimen extracted from the patient and multiplied in its laboratory. The cells are then infused into its scaffold that provides structure for the developing implant. Before NeoCart is implanted in a patient, the cell- and scaffold construct undergoes a bioengineering process in the Company's Tissue Engineering Processor (TEP). The Company has operations in the United States and Israel.

Industry, Sector and Symbol:

Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Exchange: NASDAQ
Symbol: HSGX
CUSIP:

Key Metrics:

Previous Close: $3.26
50 Day Moving Average: $3.008
200 Day Moving Average: $2.309
52-Week Range: $1.39 - $5.34
Trailing P/E Ratio: N/A
Foreward P/E Ratio: -1.38
P/E Growth: 0.000
Market Cap: $43.20M
Outstanding Shares: 13,271,000
Beta: 1.68

Profitability:

Return on Equity: -132.40%
Return on Assets: -98.23%

Debt:

Debt-to-Equity Ratio: 0.04%
Current Ratio: 2.42%
Quick Ratio: 2.42%

Additional Links:

Companies Related to Histogenics Corp.:

Consensus Ratings for Histogenics Corp. (NASDAQ:HSGX) (?)

Ratings Breakdown:	1 Hold Rating, 4 Buy Ratings
Consensus Rating:	Buy (Score: 2.80)
Consensus Price Target:	$8.75 (168.82% upside)

Analysts' Ratings History for Histogenics Corp. (NASDAQ:HSGX)

Show:

Date	Firm	Action	Rating	Price Target
9/19/2016	Needham & Company LLC	Boost Price Target	Buy	$8.00 -> $11.00
9/7/2016	William Blair	Downgrade	Outperform -> Market Perform
8/11/2016	BTIG Research	Upgrade	Neutral -> Buy	$3.50
5/12/2016	Canaccord Genuity	Reiterated Rating	Buy
11/13/2015	Cowen and Company	Lower Price Target	Outperform	$17.00 -> $12.50

(Data available from 9/24/2014 forward)

Earnings History for Histogenics Corp. (NASDAQ:HSGX)

Date	Quarter	Consensus Estimate	Actual EPS	Release Link	Conference Call
11/10/2016
8/11/2016	Q216	($0.60)	($0.61)	View	Listen
5/12/2016	Q116	($0.59)	($0.60)	View	Listen
3/10/2016	Q415	($0.59)	($0.63)	View	Listen
11/12/2015	Q315	($0.47)	($0.61)	View	Listen
8/12/2015	Q215	($0.49)	($0.58)	View	Listen
5/14/2015	Q115	($1.34)	($0.60)	View	Listen
2/26/2015	Q414	$0.66	$1.70	View	Listen

(Data available from 1/1/2011 forward)

Earnings Estimates for Histogenics Corp. (NASDAQ:HSGX)

Current Year EPS Consensus Estimate: $-2.42 EPS
Next Year EPS Consensus Estimate: $-2.36 EPS

Dividend History for Histogenics Corp. (NASDAQ:HSGX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Histogenics Corp. (NASDAQ:HSGX)
No insider trades for this company have been tracked by MarketBeat.com

Latest Headlines for Histogenics Corp. (NASDAQ:HSGX)

Date	Headline
	Histogenics (HSGX) Enters $30M Private Placement (NASDAQ:HSGX) www.streetinsider.com - September 16 at 5:20 PM
	Histogenics Corporation Announces $30.0 Million Private Placement (NASDAQ:HSGX) www.nasdaq.com - September 16 at 9:25 AM
	HISTOGENICS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securiti (NASDAQ:HSGX) biz.yahoo.com - September 16 at 9:25 AM
	BRIEF-Histogenics Corporation announces $30 million private placement (NASDAQ:HSGX) feeds.reuters.com - September 16 at 8:06 AM
	Histogenics Corporation to Present at the 18th Annual Rodman & Renshaw Global Investment Conference (NASDAQ:HSGX) finance.yahoo.com - August 31 at 10:17 AM
	Newly released market study: Histogenics Corporation (HSGX) - Financial and Strategic SWOT Analysis Review (NASDAQ:HSGX) www.live-pr.com - August 22 at 10:05 AM
	Histogenics Corp (NASDAQ:HSGX) A Momentum Pick As It Races Through Pivotal Enrollment (NASDAQ:HSGX) streetregister.com - August 19 at 8:26 AM
	Histogenics' (HSGX) CEO Adam Gridley on Q2 2016 Results - Earnings Call Transcript (NASDAQ:HSGX) seekingalpha.com - August 12 at 5:34 PM
	BTIG Upgrades Histogenics Corp. (HSGX) to Buy (NASDAQ:HSGX) www.streetinsider.com - August 12 at 5:34 PM
	BTIG Upgrades Histogenics To Buy, Sets $3.50 Price Target (NASDAQ:HSGX) finance.yahoo.com - August 12 at 5:34 PM
	Edited Transcript of HSGX earnings conference call or presentation 11-Aug-16 12:30pm GMT (NASDAQ:HSGX) finance.yahoo.com - August 12 at 8:37 AM
	Q2 2016 Histogenics Corp Earnings Release - Before Market Open (NASDAQ:HSGX) biz.yahoo.com - August 11 at 5:43 PM
	Histogenics reports 2Q loss (NASDAQ:HSGX) finance.yahoo.com - August 11 at 8:30 AM
	Histogenics Corporation Announces Second Quarter 2016 Financial and Operating Results (NASDAQ:HSGX) www.nasdaq.com - August 11 at 8:30 AM
	Histogenics Corporation to Announce Second Quarter 2016 Financial Results on August 11, 2016 (NASDAQ:HSGX) finance.yahoo.com - July 28 at 8:30 AM
	Histogenics Corporation to Present at the Canaccord Genuity Growth Conference (NASDAQ:HSGX) finance.yahoo.com - July 27 at 8:30 AM
	HISTOGENICS CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders (NASDAQ:HSGX) biz.yahoo.com - June 22 at 5:02 PM
	Manufacturing Stocks Daily Report (NASDAQ:HSGX) www.fxpips.com - June 17 at 8:15 AM
	Histogenics Corporation (NASDAQ:HSGX) Impact Score At 0 - Investor Newswire (NASDAQ:HSGX) www.investornewswire.com - May 28 at 1:18 PM
	Q1 2016 Histogenics Corp Earnings Release - Before Market Open (NASDAQ:HSGX) biz.yahoo.com - May 12 at 7:07 AM
	BRIEF-Histogenics Corp Q1 loss per share $0.60 (NASDAQ:HSGX) feeds.reuters.com - May 12 at 6:52 AM
	Histogenics reports 1Q loss (NASDAQ:HSGX) sg.finance.yahoo.com - May 12 at 6:41 AM
	Histogenics Corporation Announces First Quarter 2016 Financial and Operating Results (NASDAQ:HSGX) finance.yahoo.com - May 12 at 6:30 AM
	HISTOGENICS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits (NASDAQ:HSGX) biz.yahoo.com - May 10 at 9:16 AM
	Histogenics Corporation Acquires NeoCart® Development and Commercialization Rights for Japanese Market (NASDAQ:HSGX) finance.yahoo.com - May 10 at 9:00 AM
	SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Breaches of Fiduciary Duty by the Board of Histogencis Corporation -- HSGX (NASDAQ:HSGX) finance.yahoo.com - May 4 at 5:32 PM
	SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Histogenics Corporation for Potential Breaches Of Fiduciary Duty By Its Board of Directors (NASDAQ:HSGX) finance.yahoo.com - May 4 at 11:20 AM
	Histogenics Corporation to Announce First Quarter 2016 Financial Results on May 12, 2016 (NASDAQ:HSGX) finance.yahoo.com - April 28 at 8:30 AM
	Histogenics Corporation To Present At Needham & Company’s 15th Annual Healthcare Conference (NASDAQ:HSGX) finance.yahoo.com - March 31 at 8:30 AM
	Edited Transcript of HSGX earnings conference call or presentation 10-Mar-16 1:30pm GMT (NASDAQ:HSGX) finance.yahoo.com - March 14 at 12:31 PM
	Histogenics Corporation (NASDAQ:HSGX) Short Interest Decreased By 3.73% - Franklin Independent (NASDAQ:HSGX) www.franklinindependent.com - February 26 at 1:55 PM
	Changes To Broker Targets On Histogenics Corporation (HSGX) - Share Trading News (NASDAQ:HSGX) www.sharetrading.news - February 26 at 1:55 PM
	Histogenics Corporation to Present at Upcoming Investor Conferences (NASDAQ:HSGX) finance.yahoo.com - February 25 at 8:30 AM
	HISTOGENICS CORP Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits (NASDAQ:HSGX) biz.yahoo.com - February 2 at 4:18 PM
	4:13 pm Histogenics updates on its ongoing NeoCart Phase 3 clinical trial; 50% of patients enrolled - expect to complete enrollment by the end of Q2 2017 (NASDAQ:HSGX) finance.yahoo.com - February 2 at 4:13 PM
	Histogenics Corporation Provides NeoCart® Phase 3 Clinical Trial Enrollment Update (NASDAQ:HSGX) finance.yahoo.com - February 2 at 4:05 PM
	Histogenics Corporation to Present at 18th Annual BIO CEO & Investor Conference (NASDAQ:HSGX) finance.yahoo.com - January 26 at 8:30 AM
	Histogenics Corporation to Present at Biotech Showcase 2016 (NASDAQ:HSGX) www.nasdaq.com - January 6 at 9:01 AM
	Histogenics Corporation to Present at Biotech Showcase 2016 (NASDAQ:HSGX) finance.yahoo.com - January 6 at 8:30 AM
	HISTOGENICS CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:HSGX) biz.yahoo.com - December 21 at 8:31 AM
	Histogenics Corporation Announces Amendment to NeoCart® Phase 3 Clinical Trial Enrollment Criteria (NASDAQ:HSGX) finance.yahoo.com - December 21 at 8:15 AM
	HISTOGENICS CORP Financials (NASDAQ:HSGX) finance.yahoo.com - December 8 at 1:18 PM
	Edited Transcript of HSGX earnings conference call or presentation 12-Nov-15 1:30pm GMT (NASDAQ:HSGX) finance.yahoo.com - November 13 at 9:58 AM
	Histogenics Corp Earnings Call scheduled for 8:30 am ET today (NASDAQ:HSGX) biz.yahoo.com - November 12 at 8:30 AM
	Histogenics reports 3Q loss (NASDAQ:HSGX) sg.finance.yahoo.com - November 12 at 7:41 AM
	Q3 2015 Histogenics Corp Earnings Release - Before Market Open (NASDAQ:HSGX) biz.yahoo.com - November 12 at 7:07 AM
	HISTOGENICS CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits (NASDAQ:HSGX) biz.yahoo.com - November 12 at 6:46 AM
	Histogenics Corporation Announces Third Quarter 2015 Financial and Operating Results (NASDAQ:HSGX) finance.yahoo.com - November 12 at 6:30 AM
	Histogenics Corporation to Announce Third Quarter 2015 Financial Results on November 12, 2015 (NASDAQ:HSGX) finance.yahoo.com - October 29 at 8:30 AM
	Histogenics Corporation to Participate in Upcoming Scientific and Investor Conferences (NASDAQ:HSGX) www.noodls.com - October 1 at 10:58 AM